Screener
Ligand Pharmaceuticals LGND Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's accounts payable?
- Ligand Pharmaceuticals (LGND) reported accounts payable of $9.41M in Q2 2026.
- How has Ligand Pharmaceuticals's accounts payable changed year-over-year?
- Ligand Pharmaceuticals's accounts payable increased by 9.6% year-over-year, from $8.58M to $9.41M.
- What is the long-term trend for Ligand Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's accounts payable has grown at a -3.1% compound annual growth rate (CAGR), from $3.78M to $3.24M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Ligand Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude